Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer

Yuanyuan Wang, Yang Han, Zhongliang Guo, Yanan D Yang, Tao Ren

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The transcription co-factor TAZ plays critical roles in the regulation of human carcinogenesis. However, the pathological role for TAZ in lung cancer has remained incompletely understood. TAZ expression was examined by immunohistochemistry for 163 NSCLC tissues. TAZ expression was also examined by western blotting for 20 frozen paired NSCLC and adjacent normal lung tissues. We report that TAZ is overexpressed in non-small cell lung cancer (NSCLC) tissues and correlates with shorter patient survival. Intriguingly, we find that TAZ is overexpressed primarily in lung squamous cell carcinomas (LUSC) but not lung adenocarcinomas (LUAD) compared to normal lung tissues, and that the expression levels of TAZ are significantly higher in LUSC than LUAD. The nuclear localization of TAZ correlates worse clinical outcomes in LUSC, but not LUAD, further suggesting a prognostic value for activated TAZ in LUSC. A meta-analysis of the public datasets from TCGA, Broad institute, and Oncomine shows that the TAZ gene (WWTR1) copy numbers are significantly increased in LUSC and correlate with the increase of TAZ mRNA expression, suggesting that TAZ is overexpressed in LUSC at least partly through gene amplifications. Collectively, our results suggest that TAZ expression distinctly associates with subtypes of NSCLC and may be useful for developing novel therapeutics treating LUSC.

Original languageEnglish (US)
Pages (from-to)828-832
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume509
Issue number3
DOIs
StatePublished - Feb 12 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Cells
Squamous Cell Carcinoma
Lung
Tissue
Transcription
Epithelial Cells
Gene Dosage
Gene Amplification
Genes
Meta-Analysis
Lung Neoplasms
Carcinogenesis
Transcription Factors
Messenger RNA
Western Blotting
Immunohistochemistry
Survival
Adenocarcinoma of lung

Keywords

  • Non-small cell lung cancer
  • Nuclear localization
  • Outcome
  • Subtype
  • TAZ

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer. / Wang, Yuanyuan; Han, Yang; Guo, Zhongliang; Yang, Yanan D; Ren, Tao.

In: Biochemical and Biophysical Research Communications, Vol. 509, No. 3, 12.02.2019, p. 828-832.

Research output: Contribution to journalArticle

Wang, Yuanyuan ; Han, Yang ; Guo, Zhongliang ; Yang, Yanan D ; Ren, Tao. / Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer. In: Biochemical and Biophysical Research Communications. 2019 ; Vol. 509, No. 3. pp. 828-832.
@article{2be2497a3a0d4400b333e8d1a5a5f950,
title = "Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer",
abstract = "The transcription co-factor TAZ plays critical roles in the regulation of human carcinogenesis. However, the pathological role for TAZ in lung cancer has remained incompletely understood. TAZ expression was examined by immunohistochemistry for 163 NSCLC tissues. TAZ expression was also examined by western blotting for 20 frozen paired NSCLC and adjacent normal lung tissues. We report that TAZ is overexpressed in non-small cell lung cancer (NSCLC) tissues and correlates with shorter patient survival. Intriguingly, we find that TAZ is overexpressed primarily in lung squamous cell carcinomas (LUSC) but not lung adenocarcinomas (LUAD) compared to normal lung tissues, and that the expression levels of TAZ are significantly higher in LUSC than LUAD. The nuclear localization of TAZ correlates worse clinical outcomes in LUSC, but not LUAD, further suggesting a prognostic value for activated TAZ in LUSC. A meta-analysis of the public datasets from TCGA, Broad institute, and Oncomine shows that the TAZ gene (WWTR1) copy numbers are significantly increased in LUSC and correlate with the increase of TAZ mRNA expression, suggesting that TAZ is overexpressed in LUSC at least partly through gene amplifications. Collectively, our results suggest that TAZ expression distinctly associates with subtypes of NSCLC and may be useful for developing novel therapeutics treating LUSC.",
keywords = "Non-small cell lung cancer, Nuclear localization, Outcome, Subtype, TAZ",
author = "Yuanyuan Wang and Yang Han and Zhongliang Guo and Yang, {Yanan D} and Tao Ren",
year = "2019",
month = "2",
day = "12",
doi = "10.1016/j.bbrc.2019.01.012",
language = "English (US)",
volume = "509",
pages = "828--832",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer

AU - Wang, Yuanyuan

AU - Han, Yang

AU - Guo, Zhongliang

AU - Yang, Yanan D

AU - Ren, Tao

PY - 2019/2/12

Y1 - 2019/2/12

N2 - The transcription co-factor TAZ plays critical roles in the regulation of human carcinogenesis. However, the pathological role for TAZ in lung cancer has remained incompletely understood. TAZ expression was examined by immunohistochemistry for 163 NSCLC tissues. TAZ expression was also examined by western blotting for 20 frozen paired NSCLC and adjacent normal lung tissues. We report that TAZ is overexpressed in non-small cell lung cancer (NSCLC) tissues and correlates with shorter patient survival. Intriguingly, we find that TAZ is overexpressed primarily in lung squamous cell carcinomas (LUSC) but not lung adenocarcinomas (LUAD) compared to normal lung tissues, and that the expression levels of TAZ are significantly higher in LUSC than LUAD. The nuclear localization of TAZ correlates worse clinical outcomes in LUSC, but not LUAD, further suggesting a prognostic value for activated TAZ in LUSC. A meta-analysis of the public datasets from TCGA, Broad institute, and Oncomine shows that the TAZ gene (WWTR1) copy numbers are significantly increased in LUSC and correlate with the increase of TAZ mRNA expression, suggesting that TAZ is overexpressed in LUSC at least partly through gene amplifications. Collectively, our results suggest that TAZ expression distinctly associates with subtypes of NSCLC and may be useful for developing novel therapeutics treating LUSC.

AB - The transcription co-factor TAZ plays critical roles in the regulation of human carcinogenesis. However, the pathological role for TAZ in lung cancer has remained incompletely understood. TAZ expression was examined by immunohistochemistry for 163 NSCLC tissues. TAZ expression was also examined by western blotting for 20 frozen paired NSCLC and adjacent normal lung tissues. We report that TAZ is overexpressed in non-small cell lung cancer (NSCLC) tissues and correlates with shorter patient survival. Intriguingly, we find that TAZ is overexpressed primarily in lung squamous cell carcinomas (LUSC) but not lung adenocarcinomas (LUAD) compared to normal lung tissues, and that the expression levels of TAZ are significantly higher in LUSC than LUAD. The nuclear localization of TAZ correlates worse clinical outcomes in LUSC, but not LUAD, further suggesting a prognostic value for activated TAZ in LUSC. A meta-analysis of the public datasets from TCGA, Broad institute, and Oncomine shows that the TAZ gene (WWTR1) copy numbers are significantly increased in LUSC and correlate with the increase of TAZ mRNA expression, suggesting that TAZ is overexpressed in LUSC at least partly through gene amplifications. Collectively, our results suggest that TAZ expression distinctly associates with subtypes of NSCLC and may be useful for developing novel therapeutics treating LUSC.

KW - Non-small cell lung cancer

KW - Nuclear localization

KW - Outcome

KW - Subtype

KW - TAZ

UR - http://www.scopus.com/inward/record.url?scp=85059681542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059681542&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2019.01.012

DO - 10.1016/j.bbrc.2019.01.012

M3 - Article

C2 - 30638934

AN - SCOPUS:85059681542

VL - 509

SP - 828

EP - 832

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -